Navigation Links
Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
Date:9/4/2008

LAIYANG, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, today announced that it completed a 40-for-1 reverse stock split of its common stock which will begin trading under the symbol "GNPH."

Upon today's market open, Genesis' common stock will no longer trade under the symbol "GTEC" and will begin trading on a split-adjusted basis under the trading symbol "GNPH."

Following this reverse stock split, the Company has approximately 10,325,000 shares of common stock outstanding.

"We are pleased to complete this reverse stock split of our common stock as part of our efforts to position the company to move to a senior U.S. stock market and improve the marketability and value of our shares," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "We expect this adjustment to our capital structure to bring the Company to the attention of new investors and make our shares more attractive to them."

Stockholders who hold their shares in brokerage accounts or "street name" will not be required to take any action to exchange their shares. Stockholders of record who hold share certificates will receive a letter of transmittal requesting that they surrender their old stock certificates for new stock certificates reflecting the adjusted number of shares as a result of the reverse stock split. The Transfer Agent and Registrar for shares of GTEC's common stock is Computershare Trust Company, 350 Indiana St., #800, Golden, Colorado 80401, (303) 262-0600. They will act as the exchange agent for purposes of implementing the exchange of stock certificates.

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical
'/>"/>

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
5. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
6. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
7. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
8. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
9. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
10. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
11. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014   Sequenom, Inc. (NASDAQ: ... provides innovative genetic analysis solutions, and Mayo Medical ... services in the United States , ... patents and applications. "We have great appreciation ... care, and we welcome the opportunity to partner with ...
(Date:7/29/2014)... separated from its properties? On July 29, the prestigious ... the first Cheshire Cat experiment, separating a neutron from ... CA, and Vienna University of Technology. , Chesire Cat"Well! ... Alice in Wonderland, "but a grin without a cat! ... my life!" Alice,s surprise stems from her experience that ...
(Date:7/29/2014)... team of researchers has created a new way ... textures. These surfaces, made by self-assembly of carbon ... including controllable mechanical stiffness and strength, or ... direction. , "We have demonstrated that mechanical forces ... complex three-dimensional microstructures, and that we can independently ...
(Date:7/29/2014)... 29, 2014  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: IPXL).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... July 29, 2014, Impax Laboratories, Inc. (the "Company") issued ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4A new way to make microstructured surfaces 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2
... Mass., Dec. 15 Repligen Corporation (Nasdaq: RGEN ) ... funding to support the ongoing development of new treatments for ... grant will support the completion of preclinical GLP toxicology testing ... trials. Support from the MDA not only provides important ...
... , , , , , , , ... Board : AEMD) announced today that Dr. Jeff Schorey and Dr. ... Exosome Sciences, Inc. (ESI). Both Dr. Schorey and Dr. Comper are ... of Aethlon Medical, was recently formed to leverage the discovery that ...
... , , PLYMOUTH, Minn., Dec. 15 The Mosaic ... quarter fiscal year 2010 earnings results and financial tables on Tuesday, ... York Stock Exchange. Results will be available on Mosaic,s website ... call with presentation slides on Wednesday, January 6, 2010, to discuss ...
Cached Biology Technology:Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2
(Date:7/28/2014)... have pinpointed a mechanism in part of the brain that ... it to both type 1 and type 2 diabetes. The ... Proceedings of the National Academies of Sciences . , ... a part of the hypothalamus known as the ventromedial nucleus ... glucose levels in the blood," said lead author Sabrina Diano, ...
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
(Date:7/28/2014)... St. Jude Children,s Research Hospital study found that 73 ... doubled their risk of developing metabolic syndrome and related ... The results appear in the current issue of the ... the 1,598 adult survivors of childhood cancer in the ... risk factors like high blood pressure, abdominal obesity, elevated ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... Hunting for meat in the African rainforests has halved the ... consequences. The decline in the number of primates causes a ... this leads to a reduction in the numbers of important ... shown in new research from Lund University in Sweden. ...
... 2013 - Elsevier, a world-leading provider of scientific, technical ... announce the launch of Wound Medicine The ... and Applications . Published in print and ... is devoted to the clinical, scientific and health economics ...
... to determine mercury exposure from dental amalgam fillings may ... from fillings, according to University of Michigan researchers. ... vapor into the mouth. But both the amount of ... presents a significant health risk remain controversial. Public ...
Cached Biology News:Hunting for meat impacts on rainforest 2Elsevier announces the launch of a new journal: Wound Medicine 2Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 2Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 3
... supplied as 10X concentrated solutions. REact Buffer SetConsists ... the REact buffers and one 250 microl vial ... 1 ml vials of REact 1 Buffer four ... 1 ml vials of REact 3 Buffer and ...
Request Info...
Services include subcloning into an expression vector. Tagged protein will be expressed in small scale for testing yield and solubility and then in 1L culture for large scale affinity purification. E...
...
Biology Products: